Hi NZT,
Looking back at Clinical Trials Update 24th May:
Further, PharmAust has signed an agreement to evaluate MPL in transgenic “humanised” mice, which
will express the receptors that the COVID-19 virus binds to in humans. Efficacy in this anti-viral model
will provide further evidence of the anti-viral effects of MPL.
It was not explicitly stated who the agreement was signed with. If it was with a potential partner then I can understand the identity being excluded. I am guessing this is all under the guidance of Ergomed.
Agree with you that we as shareholders need to have better messaging so that we don't have to try and guess the details.
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-924
-
- There are more pages in this discussion • 543 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.005(2.27%) |
Mkt cap ! $100.1M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.5¢ | 21.5¢ | $194.1K | 889.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4996 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 114999 | 4 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |